The 5-year cancer-specific survival probabilities were 73.3% for CEA-positive (>5.0 ng/mL) and 88.3% for CEA-negative (≤5.0 ng/mL) cases, and 62.4% for CA19-9-positive (>37 U/mL) and 88.6% for CA19-9-negative (≤37 U/mL) cases in the survival analysis dataset (n = 188). Here, CEACAM5 is linked to cancer.